Controlling renal cell carcinoma's (RCC) metastatic growth has been a challenge for genitourinary oncologists, and a new study demonstrates how this cancer reprograms its environment to bypass the immune system.
Renal Cell Carcinoma
Treatment with AGS-003 in combination with sunitinib (Sutent) appears to be safe, well-tolerated, and associated with extended survival in patients with metastatic renal cell carcinoma (mRCC), according to new data from a phase II trial published in the Journal for ImmunoTherapy of Cancer.
Metastatic renal cell carcinoma (mRCC) patients may have improved quality of life and suffer significantly fewer side effects with a new protocol that calls for an attenuated-dose regimen of sunitinib (Sutent).
A 42-year-old woman is found to have a cystic tumor in the kidney. What is your diagnosis?
A 43-year-old woman presents with pain in the right flank. A kidney mass is found on imaging. What is your diagnosis?
Metastatic renal cell carcinoma (mRCC) can have a grim outcome, but the good news is that nivolumab (Opdivo) has demonstrated antitumor activity in patients with this disease.
Researchers at Washington University School of Medicine in St. Louis, have developed a new test that detects two proteins in urine that indicate the presence of early-stage kidney cancers.
A 20-year-old man is found to have an abnormality on imaging. A biopsy is performed. What is your diagnosis?
Patients with sarcomatoid or poor-risk renal cell carcinoma (RCC) had frequent objective responses when treated with the combination of gemcitabine (Gemzar) and sunitinib (Sutent), according to the results of a small phase II study.
Identifying gene signatures in patients with clear cell renal cell carcinoma (ccRCC) that can predict the likelihood of their disease metastasizing, as well as the site of metastasis, may help to better stratify risk assessment for the disease and plan appropriate treatment strategies.